NewswireToday - /newswire/ -
Holmes Chapel, Cheshire, United Kingdom, 2008/10/29 - Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announces the release of its new 2008–09 Synthesis and Purification Catalog.
The new 336-page catalog includes a range of products for microwave synthesis, work-up, flash purification and evaporation. To order a catalog, please go online.
This new Biotage catalog offers valuable information on applications along with comprehensive information to assist with system and consumable selection. A list of published microwave reactions provides quick reference to papers illustrating the wide-ranging benefits of microwave synthesis. The catalog also contains strategies for using solid-bound reagents to achieve higher purities, work-up solutions and scavenger selection guides.
New featured products include: the latest Biotage flash purification system, Isolera™ along with SNAP™ flash cartridges and the innovative V10 solvent evaporation system which quickly and safely dries dissolved compounds. Also Biotage has included the consumable and spare-part pricing for quick and easy reference when ordering.
The new Isolera™ FLASH purification system and new full range SNAP cartridge line, were both launched in 2008. These state-of-the-art flash chromatography tools enable chemists to easily achieve better separations in significantly shorter purification run-times.
For more information on the Biotage range of synthesis and purification products, please email product_info[.]biotage.com or order a catalog online.
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA T: +44 1477 539539 F: +44 1477 539540 E: biotage[.]scottpr.com.
Biotage (biotage.com) is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company’s products to integrated solutions and producing such products, and the Company’s ability to identify and develop new products and to differentiate its products from competitors.